How To Play The 3.77% Plunge In Antares Pharma, Inc. (ATRS)

Antares Pharma, Inc. (NASDAQ:ATRS) is trending higher in the market today as the company shares are trading 3.77% or 0.13 points down from last closing price of $3.45, reaching $3.32 at last check. Any clue why there is so much of action in the ATRS stock? The share price has dropped in 2 of the last 5 days and is up 19.79% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -466,695 shares, and in total 453405 shares valued at $1.505 million were seen changing hands compared with 920100 shares valued at $3.174 million recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the ATRS stock is near its bottom.

Antares Pharma, Inc. (ATRS) shares have notched a 3-month gain of about 19.79%, but has still advanced 26.84% year to date. By comparison, the stock sank -4.43% over the past 12 months, while it jumped 7.81% over the 1 month. The company’s market cap is around $562.56M, with its short interest ratio standing at 4.85%.

In the current trading session for ATRS, the stock witnessed two major price actions, it rose to a high of $3.47 and was down as much as $3.3 at one point. The high recorded is very low when compared to their 52-week high which is $2.53. The 52-week high is now at -15.66 distance from current price. Their recent low of $3.96 represents a 32.02% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ATRS is $5.98, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Antares Pharma, Inc. earned $-0.02 per share in the trailing 12 months and has a P/E ratio of -166. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 31.72 and lower compared to the sector’s average of 32.67. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ATRS also has P/S multiple of 6.12. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 6.55x.

The company recorded an interesting insider sale transaction by the Director on May 01, 2019. A Securities and Exchanges Commission filings show that Thomas J Garrity sold a total of 30,000 ATRS shares that day for a sum of around $80,100. The filings show that the insider now retains 190,213 shares, currently worth $631,507. Antares Pharma, Inc. (ATRS) insiders have acquired 684,419 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 204,034 shares. In total, individual insiders traded 888,453 shares in the business, which makes up 43.253% of 2,054,102 shares that were traded over a year. In the past 12 months, insiders have purchased 1,023,359 shares while the seller parted with 1,030,743 shares.

ATRS‘s last price was up 7.13% as compared to the average trading price of 50 days recorded at $3.1 while enlarging the period to 200 trading days, the average closing price was $3.17. At present, there are 163.06 million in the total number of common shares owned by the public and among those 150.9 million shares have been available to trade. The percentage of shares being held by the company management was 8.1% while institutions stake was 39.8%. The company has generated negative returns on equity over the last 12 months (-9.7%). It managed to keep its gross profit margin at 54.4% over the past 12 months.

When assessing the full upside of the ATRS stock, there is another set of technicals that should be looked into and considered. Its 3.87% gain from moving average of $3.2 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0.88 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Antares Pharma, Inc. — 3 analysts rate the stock as a buy with another 1 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $5.035 on shares of Antares Pharma, Inc. (NASDAQ:ATRS), which corresponds to 52.58% upside potential than its current market price of $3.32 and implies potential despite the recent drop in the price. However, their current target price has climbed from $4.828 a month ago and is up handily from the consensus target of $4.828 a quarter ago.

In the last five years, the EPS of the company has been roughly 23.8%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 25.2 over the last five years. The company recently recorded an increase of 100%, but this figure is rather attractive.